# Create

**Canonical:** https://apis.io/providers/create/  
**Website:** https://createmedicines.com  
**APIs profiled:** 0

CREATE Medicines is a Cambridge, Massachusetts biopharmaceutical company developing in vivo CAR (chimeric antigen receptor) cell therapies using mRNA lipid-nanoparticle (mRNA-LNP) delivery. Its platform reprograms immune cells, including T cells, NK cells, and myeloid cells, directly inside the body rather than extracting and engineering them ex vivo, with clinical and preclinical programs spanning oncology, autoimmune disease, and fibrosis. Surfaced as a portfolio company of 8vc and added to the API Evangelist network as a stub. The enrichment pipeline found no developer or API surface; this is a clinical-stage therapeutics company, not a software or platform provider, so no API artifacts were produced (none is the correct, non-fabricated result).

## Kin Score — 9.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 9.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biopharmaceutical, Cell Therapy, mRNA, Oncology, Immunology, Biotechnology

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/create/). Scores are computed from the provider's own public artifacts under a published rubric.